Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 7 studies | 29% ± 9% | |
melanocyte | 5 studies | 51% ± 20% | |
pancreatic A cell | 4 studies | 71% ± 15% | |
type B pancreatic cell | 4 studies | 57% ± 21% | |
neuroendocrine cell | 4 studies | 65% ± 19% | |
retina horizontal cell | 4 studies | 21% ± 4% | |
enteroendocrine cell | 4 studies | 44% ± 18% | |
ionocyte | 3 studies | 18% ± 0% | |
neutrophil | 3 studies | 29% ± 16% | |
pancreatic D cell | 3 studies | 63% ± 20% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
pancreas | 4 studies | 47% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 100% | 1545.48 | 1800 / 1809 | 90% | 332.53 | 423 / 472 |
adrenal gland | 100% | 12755.94 | 258 / 258 | 88% | 296.89 | 202 / 230 |
intestine | 85% | 1198.36 | 820 / 966 | 68% | 37.86 | 360 / 527 |
pancreas | 43% | 182.81 | 141 / 328 | 90% | 70.79 | 160 / 178 |
lung | 81% | 426.90 | 468 / 578 | 47% | 30.52 | 543 / 1155 |
bladder | 62% | 594.62 | 13 / 21 | 64% | 36.61 | 323 / 504 |
uterus | 82% | 533.25 | 139 / 170 | 36% | 13.81 | 163 / 459 |
prostate | 77% | 313.46 | 188 / 245 | 40% | 12.40 | 202 / 502 |
kidney | 57% | 340.34 | 51 / 89 | 57% | 29.67 | 511 / 901 |
thymus | 30% | 99.85 | 199 / 653 | 78% | 92.48 | 474 / 605 |
breast | 55% | 224.11 | 252 / 459 | 47% | 17.69 | 526 / 1118 |
spleen | 99% | 930.68 | 238 / 241 | 0% | 0 | 0 / 0 |
brain | 63% | 546.60 | 1661 / 2642 | 31% | 7.01 | 220 / 705 |
eye | 0% | 0 | 0 / 0 | 84% | 94.24 | 67 / 80 |
peripheral blood | 83% | 7913.06 | 771 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 83% | 41.47 | 24 / 29 |
stomach | 15% | 56.24 | 53 / 359 | 51% | 25.81 | 147 / 286 |
adipose | 52% | 259.45 | 626 / 1204 | 0% | 0 | 0 / 0 |
ovary | 6% | 24.34 | 10 / 180 | 37% | 13.24 | 157 / 430 |
esophagus | 13% | 58.63 | 192 / 1445 | 25% | 8.08 | 46 / 183 |
heart | 33% | 134.15 | 282 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 31% | 6.25 | 14 / 45 |
muscle | 29% | 124.63 | 229 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 22% | 75.53 | 295 / 1335 | 0% | 0 | 0 / 0 |
liver | 1% | 3.99 | 3 / 226 | 8% | 2.57 | 33 / 406 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0017186 | Biological process | peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferase |
GO_0036211 | Biological process | protein modification process |
GO_1904724 | Cellular component | tertiary granule lumen |
GO_1904813 | Cellular component | ficolin-1-rich granule lumen |
GO_0070062 | Cellular component | extracellular exosome |
GO_0035580 | Cellular component | specific granule lumen |
GO_0005576 | Cellular component | extracellular region |
GO_0016603 | Molecular function | glutaminyl-peptide cyclotransferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0008270 | Molecular function | zinc ion binding |
Gene name | QPCT |
Protein name | Glutaminyl-peptide cyclotransferase (EC 2.3.2.5) (Glutaminyl cyclase) (QC) (sQC) (Glutaminyl-tRNA cyclotransferase) (Glutamyl cyclase) (EC) Glutaminyl-peptide cyclotransferase (EC 2.3.2.5) (Glutaminyl cyclase) Glutaminyl-peptide cyclotransferase (EC 2.3.2.5) (Glutaminyl cyclase) (Glutaminyl-tRNA cyclotransferase) |
Synonyms | |
Description | FUNCTION: Responsible for the biosynthesis of pyroglutamyl peptides. Has a bias against acidic and tryptophan residues adjacent to the N-terminal glutaminyl residue and a lack of importance of chain length after the second residue. Also catalyzes N-terminal pyroglutamate formation. In vitro, catalyzes pyroglutamate formation of N-terminally truncated form of APP amyloid-beta peptides [Glu-3]-amyloid-beta. May be involved in the N-terminal pyroglutamate formation of several amyloid-related plaque-forming peptides. . |
Accessions | ENST00000404976.5 C9JS14 ENST00000650442.1 B5MCZ9 Q16769 A0A3B3IUD5 ENST00000444022.1 ENST00000338415.8 [Q16769-1] |